Immunological Aspects of Approved MS Therapeutics

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Rommer, Paulus S., Milo, Ron, Han, May H., Satyanarayan, Sammita, Sellner, Johann, Hauer, Larissa, Illes, Zsolt, Warnke, Clemens, Laurent, Sarah, Weber, Martin S., Zhang, Yinan, Stuve, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637731/
https://www.ncbi.nlm.nih.gov/pubmed/31354720
http://dx.doi.org/10.3389/fimmu.2019.01564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637731/
https://www.ncbi.nlm.nih.gov/pubmed/31354720
http://dx.doi.org/10.3389/fimmu.2019.01564

Ejemplares similares